Pfizer COVID-19 vaccine sales tumble after government guidance on the shots narrows, P3

Shidonna Raven
1 day ago
2 min read

Updated November 4, 2025

Photo / Image Source: Unsplash,

fizerOVID19 vaccine sales tumble after government guidance on the

The change in government guidance also created questions about whether insurance coverage would continue. A major industry group, America’s Health Insurance Plans, has since clarified that its members will cover the shots.

CVS Health announced earlier this month that it will not require prescriptions at its stores and clinics.

Pharmacy owner Theresa Tolle says this fall has probably been one of the more confusing seasons for her customers. Tolle runs the independent Bay Street Pharmacy in Sebastian, Florida.

She said her COVID-19 vaccine business has been busy because she has an older patient population. Many still want the shots. But she’s also had more customers tell her this year that they don’t want them.

“There’s just so many messages out there, they don’t know who to believe,” she said. “I’ve had people tell me they are afraid of it when they’ve had it many times.”

Pfizer saw U.S. Comirnaty sales drop to $870 million in the recently completed third quarter from $1.16 billion in the same time frame last year. That came after vaccine sales rose the first two quarters of the year.

Pfizer also said Tuesday that sales of its COVID-19 treatment, Paxlovid, dropped more than 50% in the quarter both in the U.S. and internationally due to lower infection rates.

Wall Street analysts also expect sales of the COVID-19 vaccine Spikevax from Moderna to tumble about 50% in the third quarter, according to the data firm FactSet.

Moderna will report its third-quarter results on Thursday.

The Myth of Mental Illness: Foundations of a Theory of Personal Conduct

How can such practices impact your health? How Why